Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Meridian Growth Fund ArrowMark Colorado Holdings, LLC | “Royalty Pharma plc is the industry's largest buyer of biopharmaceutical royalties, partnering with innovators to co-fund late-stage clinical trials and acquiring existing royalties on approved therapi” | BULL | Q1 2026 Apr 16, 2026 | View Pitch |
Latitude Global Fund Freddie Lait | “Thirty years later, the company he founded, Royalty Pharma, generates over $2bn per year in cash flow, produced by royalties on a highly diversified collection of drugs, including 7 of the top 30 in the US. The company has a 40-50% market share of all pharma royalties and remains dominant today, despite attempts at competition from large private equity firms like Blackstone. The increased costs to bring a drug to market, and the absence of a credible alternative in equity and bond markets, mean that royalties become an increasingly attractive way of funding research. Barriers to entry are also high: relationships with pharma companies are built over decades, databases of successful trials and research require time to accumulate, and royalty holding periods are a lot longer than the lifespan of the average private equity fund. The company has shown great ability in diversifying its portfolio at solid double-digit returns and we were able to acquire the shares at a highly attractive entry point. BSD Analysis: Royalty Pharma offers a unique, low-volatility entry into the biotechnology sector by acting as a provider of capital to innovators in exchange for long-term royalty streams from approved blockbusters. For 2026, the company has guided for portfolio receipts to reach nearly 3.4 billion dollars, driven by core assets like cystic fibrosis treatments and the rapid expansion of its synthetic royalty portfolio. The firm has successfully internalized its management structure, a move expected to significantly reduce operating costs and improve alignment with shareholders starting this year. While the loss of exclusivity for legacy products like Promacta presents a headwind, the pipeline of upcoming catalysts—including pivotal study results for pancreatic cancer and cardiovascular therapies—offers substantial valuation upside. With a disciplined capital allocation strategy and a recently increased dividend, Royalty Pharma is a high-quality play on pharmaceutical innovation without the binary risk of traditional drug development.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Patient Capital Management Christina Siegel Malbon | “Royalty Pharma offers highly defensive, diversified royalty income streams at a very low valuation of 5.9x forward earnings. Led by a highly capable management team, the company is poised for high-single to low-double-digit earnings growth, supplemented by aggressive share buybacks.” | BULL | Q4 2024 Jan 13, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
